Array Biopharma (ARRY) Tops Q2 EPS by 10c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Array Biopharma (ARRY) Tops Q2 EPS by 10c, Revenues Beat
February 6, 2019 7:56 AM EST
Cowen analyst Chris Shibutani raised the price target on Array BioPharma (NASDAQ: ARRY) to $23.00 (from $22.00) while maintaining a Outperform rating.
The analyst commented, "Delivery of another excellent quarter, with F2Q19 MEKTOVI/BRAFTOVI sales of $23MM handily outpacing expectations, bolsters confidence in... More
February 5, 2019 3:55 PM EST
Stifel analyst Stephen Willey raised the price target on Array BioPharma (NASDAQ: ARRY) to $29.00 (from $26.00) while maintaining a Buy rating.
Willey said Q2 confirms the value of the melanoma opportunity.
...
More
February 5, 2019 1:47 PM EST
Jefferies analyst Eun Yang raised the price target on Array BioPharma (NASDAQ: ARRY) to $24.00 (from $21.00) while maintaining a Buy rating.
Yang notes the company narrowed its Q2 net loss of strong Braftovi/Mektovi sales.
...
More
February 5, 2019 5:14 AM EST
Increasing unusual option volume: EOLS MXWL PAGP PBI PKI ARRY ASND NCR AMG MMC
...
More
